Keith A Vossel

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc New approaches to the treatment of frontotemporal lobar degeneration
    Keith A Vossel
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    Curr Opin Neurol 21:708-16. 2008
  2. ncbi Seizures and epileptiform activity in the early stages of Alzheimer disease
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, California2Memory and Aging Center, Department of Neurology, University of California, San Francisco, California
    JAMA Neurol 70:1158-66. 2013
  3. pmc ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease
    Keith A Vossel
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurocase 19:295-301. 2013
  4. pmc Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
    Pascal E Sanchez
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 109:E2895-903. 2012
  5. pmc Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
  6. pmc Tau reduction prevents Abeta-induced defects in axonal transport
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 330:198. 2010

Collaborators

Detail Information

Publications6

  1. pmc New approaches to the treatment of frontotemporal lobar degeneration
    Keith A Vossel
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    Curr Opin Neurol 21:708-16. 2008
    ..Treatment approaches for frontotemporal lobar degeneration (FTLD) are rapidly evolving with improved understanding of the disease. This brief review highlights recent advances...
  2. ncbi Seizures and epileptiform activity in the early stages of Alzheimer disease
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, California2Memory and Aging Center, Department of Neurology, University of California, San Francisco, California
    JAMA Neurol 70:1158-66. 2013
    ..We report key features of AD-related seizures and epileptiform activity that are instructive for clinical practice and highlight similarities between AD and transgenic animal models of the disease...
  3. pmc ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease
    Keith A Vossel
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurocase 19:295-301. 2013
    ..Although differences seen in a sibling pair could arise due to chance, these findings raise the possibility that apoE4 exacerbates brain pathology in FTLD through formation of neurotoxic apoE fragments and interactions with TDP-43...
  4. pmc Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
    Pascal E Sanchez
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 109:E2895-903. 2012
    ..Our findings support the hypothesis that aberrant network activity contributes causally to synaptic and cognitive deficits in hAPP mice. LEV might also help ameliorate related abnormalities in people who have or are at risk for AD...
  5. pmc Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
    ..The atrophy patterns in epsilon4 carriers may indicate that they are at greater risk for clinical progression...
  6. pmc Tau reduction prevents Abeta-induced defects in axonal transport
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 330:198. 2010
    ..Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, Aβ requires tau to impair axonal transport, and tau reduction protects against Aβ-induced axonal transport defects...